The Institute for Clinical and Economic Review (ICER) has just published its latest report on unsupported price increases of prescription drugs in the United States.
The report started with identifying the top 100 drugs with the largest sales revenue in the calendar year 2019, excluding 67 drugs whose increase in wholesale acquisition cost (WAC) was not larger than twice the increase in the medical consumer price index (CPI). The intent was to select the top 10 drugs, to determine whether there was new clinical evidence in the prior two years (2018 through 2019).
Out of 10 identified drugs, seven were not supported by new clinical evidence, unable to demonstrate any substantial clinical benefit that was not yet previously known. The total increase in spending in the U.S. over one year due to price increases for the seven drugs found to have unsupported price increases (even after rebates and other concessions) amounted to $1.2 billion.
Etanercept (Enbrel®) was determined to have had the single largest impact on national drug spending among all drugs evaluated in this report. This net price (almost 9%) change over the assessed four quarters resulted in an estimated increase in drug spending of $403 million.
As state lawmakers continue to pursue punitive legislation, this report provides an explicit and independent approach to evaluating the evidence behind price hikes in America.